Background. Dual blockade of the renin-angiotensin system (RAS) has been claimed to have a specific renal protective effect in chronic kidney disease (CKD). The present short-term study reports on the feasibility of dual blockade in a consecutive group of patients with CKD stage 3-5. Methods. Forty-seven CKD patients, mean age 59years, with mean estimated glomerular filtration rate (GFR) 26 ml/min/1.73 m² (range 13-49) and blood pressure (BP) 133/78 mmHg, were block randomized in an open study to 16weeks of monotherapy with increasing doses of RAS blockade aiming at enalapril 20mg o.d. or candesartan 16 mg o.d. Thereafter, the complementary drug was added in incremental doses over a period of 5weeks aiming at combined enalapril 20mg and candesartan 16mg for 3weeks. Seventy-five percent of the patients were known to be RAS blockade tolerant. Blood samples and BP were measured every 2-3weeks. Doses of study medication were reduced in case of hyperkalemia >5.5mmol/l, a sustained rise in p-creatinine >30% or symptomatic hypotension. Results. Twenty-one patients (45%) did not tolerate dual blockade in aimed dosages due to unacceptable p-creatinine increase (n = 12, including two study withdrawals), hypotension (n = 6), general discomfort (n = 2) or unmanageable hyperkalemia (n = 1). Hyperkalemia >5.5mmol/ l was seen in seven patients (15%). The reduced-dose group had baseline lower eGFR and diastolic BP. Conclusions. Forty-five percent of CKD stage 3-5 patients did not tolerate dual RAS blockade with 20mg enalapril and 16mg candesartan daily, primarily due to loss of renal function or hypotension. Hyperkalemia could be managed in most patients. Caution is recommended when giving this treatment to patients with advanced CKD.
Introduction
Inhibition of the renin-angiotensin system (RAS) is widely used in cardiovascular and renal disease. Combined treatment with an angiotensin-converting enzyme inhibitor (ACEI) and an angiotensin receptor blocker (ARB) has been suggested to afford better organ protection than seen with monotherapy, particularly in patients with mild chronic kidney disease (CKD) [1, 2] . In cardiovascular studies, a beneficial effect of this dual blockade of the RAS has been shown in heart failure [3] [4] [5] but was only modest in reducing atherosclerotic events in patients after acute myocardial infarction [6] and was not present in patients at high vascular risk with more frequent adverse events compared to monotherapy [7] . Renal outcome in the ONTARGET study was surprisingly worse with combined ramipril and telmisartan treatment than with monotherapy [8] . These results have resulted in an ongoing debate on the rationale of the use of dual blockade in clinical practice [9, 10] . The ONTARGET methodology with respect to renal endpoints has been questioned [11] . Previous studies of combined ACEI and ARB treatment in mostly mild to moderate CKD have generally reported few side effects [12] . The issue of feasibility of dual blockade in advanced CKD has rarely been addressed [13] . This is the aim of the present report.
Methods

Patients
Forty-seven consecutive patients, 38 men and nine women, were enrolled in this study, which is part of a randomized, open ongoing trial that started in September 2005 on the vascular effects of enalapril, candesartan and their combination in CKD. The main trial has been designed to test the hypothesis that dual RAS blockade with an ACEI and ARB has a preferential effect on arterial stiffness evaluated by pulse-wave analysis and pulse-wave velocity compared to monotherapy with either one of the drugs. Feasibility is not a preplanned endpoint but GFR, proteinuria and laboratory tests of blood are secondary endpoints. Patients were recruited from the outpatient nephrology clinic, Herlev University Hospital. The mean age was 59years (range 31-75) and all patients were Caucasians. All patients gave informed consent and the study was approved by the Ethical Committee of Copenhagen County. The authors adhered to the Declaration of Helsinki, and the study was monitored by the Good Clinical Practice (GCP) unit at Copenhagen University Hospitals. The trial is registered by EudraCT number 2005-001568-29. The eligibility criteria for patients entering the study were pre-dialysis CKD with plasma creatinine between 150 and 350μmol/l, plasma potassium <5.6mmol/l (normal values=3.5-5.0mmol/l), systolic blood pressure (BP) >109mmHg and age between 18 and 75years. None of the patients were to be treated with corticosteroids, non-steroidal anti-inflammatory drugs, aldosterone antagonists or dual blockade with RAS inhibition at the entry of the study. About 75% of the patients were treated with ACEI or ARB before enrolment and thus were known to be RAS blockade tolerant. No patients had previously experienced any adverse events to RAS inhibition. Additionally, most were treated with furosemide and non-ACEI/ARB antihypertensives, which were continued during the trial. All patients had previous isotope renography when referred to the nephrology outpatient clinic as part of the routine renal investigation program. None of the patients had previously been diagnosed with renal artery stenosis. Six patients had chronic glomerulonephritis, six had polycystic kidney disease, five had nephrosclerosis, two had diabetic nephropathy, two had other renal disease and 26 had chronic nephropathy of unknown aetiology.
Study protocol
In order to ensure close balance of the numbers in each group at any time during the trial, block randomization was used [14] . In every block of 10 participants, five would be allocated to each arm of the trial.
Monotherapy period. Randomization of patients treated with either an ACEI or an ARB prior to the study was carried out by drawing a closed envelope to ensure that half of the patients had enalapril for the first 16 weeks and the other half had candesartan the first 16weeks. Randomization of patients not treated with an ACEI or ARB prior to the study was likewise carried out by drawing an envelope from a bag to ensure that half of the patients had enalapril in the first 8weeks and candesartan in the following 8weeks and the other half of the patients had candesartan in the first 8weeks and enalapril in the following 8weeks. By this means, tolerance to either drug was demonstrated in the patients not previously treated with RAS blockers before dual blockade. In either patient group, doses were increased gradually over a period of 8weeks from enalapril 5 mg to 20 mg and from candesartan 4 mg to 16 mg, given once daily. All randomizations were carried out by the GCP-trained nurse staff members of the outpatient clinic without any conflict of interest in the trial.
Dual blockade period. In all patients, after 16weeks of monotherapy with either enalapril or candesartan, the complementary drug was added in incremental doses over a period of 5weeks, aiming at reaching a combination of enalapril 20mg and candesartan 16mg and maintaining this full dose of dual blockade for 3weeks. The therapeutic goal was a systolic blood pressure of 130mmHg or below and a diastolic blood pressure of 80mmHg or below according to the K/DOQI guidelines [15] . Additional antihypertensive treatment was simultaneously reduced, discontinued or added as needed.
All patients were followed in our outpatient nephrology clinic. BP and clinical chemistry parameters of renal function were measured at baseline and every 2-3weeks throughout the study. Urinary albumin excretion was measured at the start and end of combination therapy. Renal criteria for withdrawal were intractable hyperkalaemia >6.0mmol/l and/or sustained increase in baseline plasma creatinine >30%.
Feasibility. Feasibility of treatment was defined as tolerance to dual RAS blockade without the need of dosage reduction.
Management of hyperkalaemia, excess rise in plasma creatinine and hypotension. Hyperkalaemia during treatment was managed with dietary potassium restriction and/or furosemide to increase potassium excretion. At the first occurrence of hyperkalaemia, patients received general advice about dietary restrictions on potassium. In case of persistent hyperkalaemia, patients were advised by a dietician. In patients to be increased in study medication, furosemide was prescribed or dosage increased if plasma potassium >5.0mmol/l. When dosage of enalapril or candesartan was unchanged, the limit for start of furosemide or dose increase was plasma potassium 5.5mmol/l.
Increase in baseline plasma creatinine >30% was treated with reduced dosage of study medication and control of renal function after 1week.
In case of symptomatic hypotension, the dose of other antihypertensive medicine was reduced before any reduction in the study medication.
If these measures failed, the patient was judged not to tolerate the full dose of dual blockade, and the dose of enalapril and/or candesartan was maintained at a lower level for the rest of the study.
Blood pressure measurement, clinical chemistry and GFR estimation. Auscultatory BP was measured after at least 10min of rest. Korotkoff sound phase 5 was used for diastolic pressure recording. The mean of the last two out of three BP measurements was used for analysis. Plasma creatinine was analyzed using reagents from Vitros Chemistry 5.1 which are compatible with the isotope dilution mass spectrometry method. Plasma potassium and other clinical chemistry parameters were measured using standard methods. GFR was estimated by the six-variable Modification of Diet in Renal Disease formula [16] .
Statistics
Differences in baseline parameters between patients receiving full dual blockade dosage and patients completing the study with reduced dosage were evaluated by Student's t-test for independent data. Differences in the frequency of diabetes mellitus, background antihypertensive medication and in previous cardiovascular events were analyzed by using a two-tailed Fisher's exact test. Differences in parameters during the start and after completion of dual blockade were analyzed by Student's t-test for dependent data, and differences in parameters between patients receiving full and reduced dosages were analyzed by Student's t-test for independent data. If the distribution of data was skewed, logarithmic transformation of the data was performed before analysis and the data expressed as the geometric mean with range in brackets. When values were normally distributed, data are expressed as mean values±standard deviations (SD). All tests were two-sided. A P-value <0.05 was considered significant. Data were analyzed by use of a statistical computer program (Statistica 6.1, StatSoft Inc., OK, USA).
Results
Twenty-one of the patients (45%) failed to tolerate full dual blockade with enalapril and candesartan, and had to be given lower doses of one or both of the drugs, or in two The systolic BP during monotherapy with ACEI/ARB just before start of dual blockade is for the total group 133 ± 19, for the full dosage group 134 ± 20 and for the reduced dosage group 129 ± 15.
Data given in bold = geometric mean given due to log transformation of data with range in brackets. P-value given if significant as: *P < 0.05, **P < 0.01, ***P < 0.001. cases withdrawn from the study. The mean reduced doses of candesartan and enalapril in the 19 patients continuing the study were 8 ± 4 and 11 ± 6 mg, respectively. Baseline characteristics in all patients and in those tolerating full and reduced dual blockade are shown in Table 1 . Furthermore, baseline characteristics of BP and kidney function are shown in the first column in Table 3 . Previous treatment with an ACEI significantly increased the tolerability of full-dosage RAS blockade, but otherwise no background antihypertensives showed any difference between the two groups ( Table 1) . Baseline values of eGFR and diastolic BP were significantly lower, and p-potassium and p-urea were higher in the reduced dosage group than in the full-dosage group (Table 3) .
Causes of dosage reduction and withdrawal are given in Table 2 . Two patients were withdrawn due to severe increases in plasma creatinine of 40% and 131%, respectively, leading to hospitalization of one of the patients. Both of these patients regained their usual level of renal function after discontinuation of study medication, and in the remaining patients, renal function was acceptable after reduction in study medication. Apart from the six patients with symptomatic hypotension, mild transient hypotensive symptoms occurred in another six patients without the need of dosage reduction. Hyperkalemia with plasma potassium >5.5mmol/l was seen in seven patients (15%) after the start of dual blockade. These were treated with potassium-restricted diet and/or advice from a dietician. Furosemide was started in three and increased in four of these seven patients. Additionally, one of the study participants was started on furosemide and eight received an increased dose because of hyperkalemia (5.1-5.5mmol/l), crural edema or a high BP. Only one patient was reduced in the study medication because of hyperkalemia. Two patients had upper respiratory infections while on full-dose dual blockade, and doses were reduced because of general discomfort.
Changes in BP and renal function during combined enalapril and candesartan treatment are shown in Table 3 . In all patients, significant decreases were seen in systolic and diastolic BP, urinary albumin excretion and eGFR, and increases were seen in p-creatinine and p-urea during the 8-week dual RAS blockade. The mean increase in p-creatinine was highest after 5weeks of dual RAS blockade with 33±43μmol/l in the reduced group and 10±30μmol/l in the full-dosage group. This difference between the groups was significant (P < 0.05), but disappeared after 8weeks. The corresponding mean eGFR after 5weeks of dual RAS blockade was reduced by 3.2 ml/min/1.73 m² in the reduced-dosage group versus 1.4ml/min/1.73m² in the fulldosage group (NS). However, these mean values include a wide interval of GFR changes ranging from a reduction of 36% to an increase in GFR of 34% after 8weeks of dual blockade. Even though the mean systolic BP was reduced 3-fold after 5weeks of dual RAS blockade in the reduceddosage group compared to the full-dosage group, no significant difference was found. Furthermore, there were no significant differences in mean changes in diastolic BP, p-urea, p-potassium or u-albumin excretion during the 8-week dual RAS blockade when comparing the reducedversus the full-dosage groups.
Discussion
The present study shows that, in CKD stage 3-5, full dual RAS-blocking therapy with 20 mg enalapril and 16 mg candesartan daily was not feasible in 45% of 47 patients, in most cases because of loss of renal function or symptomatic hypotension. In 40% of the patients, the dual blockade was tolerated in reduced dosage and in two patients it had to be withdrawn. Severe hyperkalemia was seen in 15% of the patients but was manageable in all but one. The reduced-dosage group was characterized by lower baseline diastolic BP and eGFR and a higher p-urea and p-potassium. Furthermore, more patients in the reduced-dosage group had not previously been treated with RAS-blocking drugs.
Although the use of blockers of the RAS has contributed to renoprotection in CKD, there is still need for development of better treatment regimes in order to reduce endstage renal disease and the associated high risk of cardiovascular disease. The rationale for combined RAS blockade with ACEI and ARB is based on the assumption that RAS is involved in the pathogeneses of CKD progression and that a more complete RAS inhibition might be achieved by combined blockade as compared to monotherapy. The optimal dose of ACEI and ARB in chronic renal failure has not been established. Most ACEI or their active metabolites are excreted renally, and dose reductions in patients with renal insufficiency has been recommended in order to reach plasma levels comparable to levels found in patients with normal renal function [17] . On the other hand, it has been suggested that additional benefit on proteinuria and renoprotection may be reached by the use of high-dose RAS blockade [1] . In the present study, the doses of 20mg enalapril and 16mg candesartan were moderate and combined treatment was initiated by the add-on of low dose enalapril or candesartan, respectively, to welltolerated monotherapy of the other drug. Despite that cautious regime, side effects requiring dosage modifications were frequently seen.
It is well known that the start of RAS-blocking therapy may lead to a fall in GFR due to a preferential dilating effect on the efferent glomerular arterioles [18] . In the present study, we observed that combined therapy with enalapril and candesartan for 8weeks caused a modest mean fall in estimated GFR of 7% when compared to monotherapy, but including a wide interval of GFR changes. This might be caused by an additional dilatating effect on the efferent arterioles and thereby lowering of the intraglomerular capillary pressure when RAS-blocking monotherapy was changed to dual blockade. The observed significant reduction in proteinuria during combined blockade might be explained by the same mechanism. The 'safety limit' for increase in p-creatinine was 30% from baseline. This is based on the previously demonstrated strong association existing between acute increases in serum creatinine of up to 30%, stabilizing the first 2months of ACEI therapy and long-term preservation of renal function [19] . In previous studies of renal patients, dual blockade has in general been safe and well tolerated [13, [20] [21] [22] [23] [24] [25] [26] . None of the dual blockade studies in advanced CKD have reported on increases in p-creatinine >30% or study withdrawal due to Dual blockade in chronic kidney disease 845 increases in p-creatinine [13, 22, [24] [25] [26] . A greater antiproteinuric effect has been observed with combined treatment than monotherapy in optimal dosage [13, 20, 21, 23] . So far, the only study conducted on hard renal endpoints in patients with advanced kidney disease treated with ACEI versus ARB versus combination therapy has been the CO-OPERATE study [23] . Unfortunately, the results of that study have been questioned [27] . Several factors might explain the higher occurrence of increases in p-creatinine in our study compared to the literature. Firstly, patients in our study had more severe renal failure with baseline eGFR of 26ml/min/1.73m², which is about 10ml/min/1.73m² less than in previous studies in advanced CKD [22] [23] [24] 26] . In accordance with this, patients not tolerating full-dosage treatment had lower eGFR. Secondly, the target dose in our study was higher compared to some of the mentioned studies [24] [25] [26] but comparable with other studies, even though description on the exact doses used is not always clear [13, 22, 23] . Finally, even though a previous isotope renography had been performed, this does not exclude the presence of renal vascular disease in some patients.
Interestingly, baseline diastolic BP was 8mmHg lower in the reduced-dosage group compared to the full-dosage group, and furthermore, there was a tendency towards a more pronounced BP reduction in the reduced-dosage group (P = 0.07), which is in accordance with the need of dose reduction due to symptomatic hypotension in six of the patients. This implies that patients with a lower systemic BP are less tolerant to full dual blockade. In all patients, mean systolic and diastolic BP fell during 8weeks of dual RAS blockade by 9/3mmHg, respectively, which is in accordance with other studies in this patient group [22, 24, 25] . Dizziness was reported in total in 12 patients (26%). Frequencies of symptomatic hypotension of 7% and 9.5% have been reported in previous studies on dual blockade in advanced CKD [13, 26] . In another study, hypotension was the cause of withdrawal in 5% of the patients [25] .
Hyperkalemia is a well-known adverse event of ACEI or ARB when treating patients with renal impairment [28] . In our study, 15% experienced hyperkalemia, defined as a ppotassium >5.5mmol/l, which could be managed by diuretics and dietary advice in all but one case. We did not find any overall significant change in p-potassium at 2.5, 5 and 8weeks of dual blockade (Table 3) , which probably reflects that the p-potassium values have been modified by the treatment described above. No patients were excluded due to hyperkalemia, and only one patient had to be reduced in the dose of dual blockade because of persistent hyperkalemia despite dietary restrictions and furosemide. Other studies in advanced CKD have recorded hyperkalemia in about 8-12% of patients in combination treatment [13, 23, 26] , which is in accordance with our results.
Recently, data on renal outcomes in the ONTARGET study have been published [8] . Dual blockade was compared to monotherapy with an ACEI or an ARB in 25 620 patients at high cardiovascular risk, of whom 24% had a GFR <60ml/min/1.73m² and 1% had a GFR <30 ml/min/1.73m². Dual blockade was found to decrease the progression of microalbuminuria to macroalbuminuria more than in those assigned ACEI, but it was also found to worsen major renal outcomes as incidences of dialysis, doubling of serum creatinine and death [8] . Unfortunately, there is limited information on these renal events; the frequency of acute dialysis was high and there was no significant difference between incidences of chronic renal failure in the two monotherapy groups and dual blockade group. The study does not permit any conclusion on the effect of dual blockade in primary renal disease. In the wake of these results, the rationale for treatment with dual blockade has been debated [10] . Messerli recommends rather drastically that dual RAS blockade should no longer be used in clinical practice [9] . A decision about this should probably await ongoing major trials on dual blockade such as the VA NEPHRON D [29] . Our main trial on arterial function during dual blockade in CKD will hopefully contribute to an understanding of whether this treatment affords better cardiovascular protection than monotherapy.
Study limitations
This study is a part of an ongoing trial focusing on arterial stiffness. Thus, the study has not been designed to look at tolerability, although GFR, proteinuria and laboratory tests of blood were preplanned secondary endpoints. The intention was to report our experiences with dual RAS blockade in advanced CKD, a group in which few studies on dual RAS blockade have been conducted. Previous treatment with an ACEI was more frequently seen in the group of patients tolerating full-dose RAS blockade (Table 1) indicating some degree of selection bias in the study population.
In conclusion, we have found that initial dual blockade with enalapril and candesartan in patients with CKD stage 3-5 required dosage reduction in about half of the patients. Careful monitoring and dose adjustments were necessary in order to manage hyperkalemia, hypotension and too drastic loss of renal function. Thus caution is recommended when giving this treatment to patients with advanced CKD.
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